Literature DB >> 35507276

The potential anti-osteoporotic effect of exercise-induced increased preptin level in ovariectomized rats.

Khaled Abdelfattah Abulfadle1, Rania Refaat Abdelkader Atia1,2, Heba Osama Mohammed3, Rania Saad Ramadan3, Nourelhuda A Mohammed4,5.   

Abstract

Osteoporosis increases bone fragility and fractures. Preptin hormone is regulated by moderate exercise training and increases bone formation. Therefore, this study was conducted to see how estradiol administration and moderate exercise training affected osteoporotic changes in ovariectomized (OVX) rats. To achieve this aim, 36 healthy adult female Wistar albino rats were randomized into Sham, OVX, ovariectomized estradiol-treated (OVX + E) (OVX + E rats were treated using subcutaneous estradiol benzoate 2.5 μg/kg body weight/day), ovariectomized practicing moderate exercise training, ovariectomized estradiol-treated and practiced a moderate exercise training, and ovariectomized alendronate-treated (OVX + Alen) (OVX + Alen rats were treated orally with alendronate 3 mg/kg body weight/week) groups. Alendronate was used as a standard anti-osteoporotic drug. Moderate exercise training, including therapy with estradiol and alendronate for OVX rats began on the fourth week and lasted for six weeks. Results showed that OVX rats had estrogen and preptin deficiency in serum. These deficiencies were associated with a significant increase in bone resorption biomarkers (urinary deoxypyridinoline and hydroxyproline), and bone formation biomarkers (serum osteocalcin and bone-specific alkaline phosphatase). Also, serum pro-inflammatory cytokines (tumor necrosis factor alpha and interleukin-6) were increased, while bone osteopontin (OPN) expression was decreased. Subsequently, the osteoporotic alterations were verified based on histopathological changes. From the results, estradiol therapy and moderate exercise training significantly improved these findings to the same extent as that of the standard alendronate treatment. Therefore, through their anti-inflammatory properties, increasing bone OPN expression, and regulating serum preptin; estradiol therapy and moderate exercise training can reduce osteoporotic alterations in OVX rats. Thus, combined estradiol therapy and moderate exercise training could be a promising potential therapeutic protocol to reduce postmenopausal osteoporosis. Also, targeting serum preptin and bone osteopontin regulation could have a critical role in the treatment of postmenopausal osteoporosis.
© 2022. The Author(s), under exclusive licence to Japanese Association of Anatomists.

Entities:  

Keywords:  Moderate exercise; Osteopontin; Osteoporosis; Ovariectomy; Preptin

Year:  2022        PMID: 35507276     DOI: 10.1007/s12565-022-00666-7

Source DB:  PubMed          Journal:  Anat Sci Int        ISSN: 1447-073X            Impact factor:   1.741


  40 in total

Review 1.  Exercise for the prevention of osteoporosis in postmenopausal women: an evidence-based guide to the optimal prescription.

Authors:  Robin M Daly; Jack Dalla Via; Rachel L Duckham; Steve F Fraser; Eva Wulff Helge
Journal:  Braz J Phys Ther       Date:  2018-11-22       Impact factor: 3.377

2.  Bone biomarkers of ovariectomised rats after leptin therapy.

Authors:  Khaled A Abdel-Sater; Hamdy Mansour
Journal:  Bratisl Lek Listy       Date:  2013       Impact factor: 1.278

3.  Effect of 17beta-estradiol or alendronate on the bone densitometry, bone histomorphometry and bone metabolism of ovariectomized rats.

Authors:  L H da Paz; V de Falco; N C Teng; L M dos Reis; R M Pereira; V Jorgetti
Journal:  Braz J Med Biol Res       Date:  2001-08       Impact factor: 2.590

4.  Effect of soybeans and sword beans on bone metabolism in a rat model of osteoporosis.

Authors:  Jae Soon Byun; Sang Sun Lee
Journal:  Ann Nutr Metab       Date:  2010-01-28       Impact factor: 3.374

5.  The antidepressant bupropion exerts alleviating properties in an ovariectomized osteoporotic rat model.

Authors:  Hatem M Abuohashish; Mohammed M Ahmed; Salim S Al-Rejaie; Kamal E H Eltahir
Journal:  Acta Pharmacol Sin       Date:  2014-12-29       Impact factor: 6.150

6.  Effects of cyclic mechanical stretching on the mRNA expression of tendon/ligament-related and osteoblast-specific genes in human mesenchymal stem cells.

Authors:  Yi-Jane Chen; Chien-Hsun Huang; I-Chi Lee; Yu-Tsang Lee; Min-Huey Chen; Tai-Horng Young
Journal:  Connect Tissue Res       Date:  2008       Impact factor: 3.417

7.  Concentrations of preptin, salusins and hepcidins in plasma and milk of lactating women with or without gestational diabetes mellitus.

Authors:  Suleyman Aydin; Onder Celik; Bilgin Gurates; Ibrahim Sahin; Mustafa Ulas; Musa Yilmaz; Mehmet Kalayci; Tuncay Kuloglu; Zekiye Catak; Aziz Aksoy; Ibrahim Hanefi Ozercan; Selahattin Kumru
Journal:  Peptides       Date:  2013-09-20       Impact factor: 3.750

8.  An NMR metabolomic study on the effect of alendronate in ovariectomized mice.

Authors:  Shin-Yu Chen; Hui-Tzu Yu; Ju-Po Kao; Chung-Chun Yang; Shen-Shih Chiang; Darya O Mishchuk; Jeng-Leun Mau; Carolyn M Slupsky
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

9.  Effects of 12-week exercise training on osteocalcin, high-sensitivity C-reactive protein concentrations, and insulin resistance in elderly females with osteoporosis.

Authors:  Nayoung Ahn; Kijin Kim
Journal:  J Phys Ther Sci       Date:  2016-08-31

10.  Assessment of Preptin peptide level in the sera of rachitic children and in breast milk of their mothers.

Authors:  Gihan M Bebars; Salem A Sallam; Shereen S Gaber; Alshimaa H Abdelaziz
Journal:  Ital J Pediatr       Date:  2019-03-07       Impact factor: 2.638

View more
  1 in total

1.  A Comparison of the Antiosteoporotic Effects of Cornelian Cherry (Cornus mas L.) Extracts from Red and Yellow Fruits Containing Different Constituents of Polyphenols and Iridoids in Osteoblasts and Osteoclasts.

Authors:  Eunkuk Park; Tomasz Sozański; Chang-Gun Lee; Alicja Z Kucharska; Dominika Przybylska; Narcyz Piórecki; Seon-Yong Jeong
Journal:  Oxid Med Cell Longev       Date:  2022-10-03       Impact factor: 7.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.